



Media Releases » Torrent Pharma announces Q3 FY 2016-17 Results. Declares Interim Dividend of 200% February 3rd, 2017

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the Quarter ended 31st Dec 2016.

Financial Highlights	Q3 FY 2017	Q3 FY 2016	Q3 FY 2016	Q3 FY 2016	Q3 FY 2016
Revenue	1443	1542	48%	1443	1542
EBIDTA	365	672	48%	1198	1444
% Revenue	25%	44%	27%	47%	47%
PAT (after Exceptional Items)	229	290	38%	244	133
% Revenue	16%	19%	16%	17%	17%
PAT (after Exceptional Items)	124	296	31%	124	148
% Revenue	8%	19%	8%	8%	9%
EPS	11.5	17.1	33%	43.1	88.1

Quarterly Financials

- For Q3 FY 2016-17 revenues were at Rs. 1443 crores as against Rs. 1542 crores during the same period last year.
- EBIDTA for Q3 FY 2016-17 was at Rs. 365 crores as against Rs. 672 crores during the same period last year.
- PAT for Q3 2016-17 was at Rs. 229 crores as against Rs.290 crores during the same period last year.
- Previous period include exceptional revenues and profits which was primarily on account of the launch of a new product in US market, which had limited competition.
- Research and development spend during the quarter was up by Rs. 36 crores, from Rs. 59 crores in the same period previous year to Rs. 95 crores.
- Company declared an interim dividend of 200 percent. (Rs. 10/- per share)

Q3 PERFORMANCE HIGHLIGHTS

India Business

- Domestic formulation business recorded revenues of Rs. 503 crores for Q3 FY 2016-17 v/s Rs. 449 crores for the same period last year, showing 12% growth.

USA

- US business recorded revenues of Rs. 310 crores for Q3 FY 2016-17 v/s Rs. 558 crores for the same period last year.
- Previous period include exceptional revenues, primarily on account of the launch of a new product which had limited competition.

Germany

- German business recorded revenues of Rs. 203 crores for Q3 FY 2016-17 v/s Rs. 164 crores for the same period last year, showing 24% growth.

Brazil Business

- Brazilian business recorded revenues of Rs. 159 crores for Q3 FY 2016-17 v/s Rs. 118 crores for the same period last year, showing 35% growth.

YTD PERFORMANCE HIGHLIGHTS

- Research and Development spend during the period was up by Rs. 124 crores, from Rs.172 crores in the same period previous year to Rs. 296 crores.

India Business

- Domestic formulation business recorded revenues of Rs. 1,509 crores for YTD FY 2016-17 v/s Rs. 1,383 crores for the same period last year, showing 9% growth. Discontinuance of certain promotional schemes and hygiene initiatives has impacted the business in short term however it will have positive impact in long term.

USA

- US business recorded revenues of Rs. 1,065 crores for YTD FY 2016-17 v/s Rs. 2,158 crores for the same period last year.
- Previous period include exceptional revenues, primarily on account of the launch of a new product which had limited competition.
- ANDA filed during the quarter were 4 and during the period 10.

Germany

- German business recorded revenues of Rs. 577 crores for YTD FY 2016-17 v/s Rs. 485 crores for the same period last year, showing 19% growth.

Brazil Business

- Brazilian business recorded revenues of Rs. 484 crores for YTD FY 2016-17 v/s Rs. 387 crores for the same period last year, showing 25% growth.

Exceptional Items during the Q3 FY 15-16 and YTD FY 15-16 represents write off of goodwill of Rs. 194 crores arising on account of amalgamation of Zyg Pharma Private Ltd. with the Company.

About Torrent Pharma

Torrent Pharma, with annual revenues of more than Rs. 6600 crores is the flagship Company of the Rs. 18,300 crores Torrent Group.

Torrent Pharma continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset) in India. Its widespread international presence also includes several markets where Torrent is amongst the leading pharmaceutical companies in the respective countries.

Torrent has a fully equipped Research Center, employing almost 900 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi, Sikkim, Dahej, Pithampur and Vizag have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.

